Replimune adds a $55M round and some expert help as it pursues next-gen oncolytics R&D
Some of the pioneers in oncolytics drug development have gone back to the venture well to finance their latest play in the field. Replimune, which got started in Oxford and is based in Woburn, MA, tanked up with $55 million in venture cash. That money is being used to position the company for its first round of clinical work.
Replimune is bringing in a recognized expert in the immuno-oncology field as CMO alongside the round. The biotech recruited Howard Kaufman, who had been chief of the Division of Surgical Oncology at the Rutgers Robert Wood Johnson Medical School and from 2014-2016 was president of the Society for the Immunotherapy of Cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.